This finding is significant, since both murine and human pancreatic tumours are sparse in immune cells and are therefore considered immunologically ‘cold’.61 Accordingly, most patients with pancreatic cancer do not benefit from immunotherapies such as PD-1/CTLA-4 checkpoint blockade. The gene discussed is CTLA4; the disease is pancreatic neoplasm.